Cannabis Users Require More Sedation for Endoscopy 

Cannabis Users Require More Sedation for Endoscopy 

Bethesda, MD (May 21, 2022) — Patients who use cannabis required higher levels of sedation during gastric endoscopies than non-users, according to research to be presented at Digestive Disease Week® (DDW) 2022. As cannabis is legalized in more places and usage rises, clinicians should be aware of patients’ habits and prepare themselves and their patients for increased sedation and accompanying risks, researchers said. 

“Patients didn’t have increased awareness or discomfort during procedures, but they did require more drugs,” said Yasmin Nasser, MD, PhD, lead researcher on the study and assistant professor at Snyder Institute for Chronic Diseases Cumming School of Medicine University of Calgary.  

Researchers conducted a prospective cohort study of 419 adult outpatients undergoing endoscopic procedures at three Canadian centers. Procedures were conducted under conscious sedation, which leaves the patient relaxed and comfortable but partially conscious during the procedure.  

Each patient completed two questionnaires, one before the procedure about their cannabis use and another afterwards indicating their awareness and comfort level during the procedure. The questionnaires were analyzed along with details about the use of the sedatives midazolam, fentanyl and diphenhydramine during the procedure. 

Cannabis use was associated with increased odds of requiring higher total sedation—defined as more than 5 mg of midazolam, or more than 100 mcg of fentanyl, or the need for diphenhydramine—during gastroscopy, an endoscopic procedure that begins with insertion of a tube and camera through the throat. Cannabis use was not associated with higher use of sedation during colonoscopy. Gastroscopy generally requires more sedation than colonoscopy because the inserted scope causes irritation in the upper part of the gastrointestinal tract, often triggering the gag reflex. Cannabinoid use was not independently associated with fentanyl use or adverse events, nor was it associated with intra-procedural awareness or discomfort. 

This study looked at whether patients were users or non-users of cannabis, but did not examine the timing, quantity or route of cannabis intake prior to procedure, whether it was inhaled, vaporized, ingested or otherwise. Researchers say these variables could be the basis for future study.  Also, researchers only examined the impacts of baseline cannabis use during procedures that use conscious sedation and did not examine its impact on propofol sedation, which is more commonly used in the U.S.  

DDW Presentation Details 

Dr. Nasser will present data from the study, “Baseline cannabinoid use is associated with increased sedation requirements for outpatient endoscopy,” abstract Sa1022, on Saturday, May 21, at 12:30 p.m. PDT.  For more information about featured studies, as well as a schedule of availability for featured researchers, please visit 


Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 21 – 24 in San Diego, California and virtually. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at